NanJing Pharmaceutical Co Ltd
Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nan… Read more
Market Cap & Net Worth: NanJing Pharmaceutical Co Ltd (600713)
NanJing Pharmaceutical Co Ltd (SHG:600713) has a market capitalization of $968.69 Million (CN¥7.11 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #11287 globally and #2625 in its home market, demonstrating a 2.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NanJing Pharmaceutical Co Ltd's stock price CN¥5.43 by its total outstanding shares 1308932215 (1.31 Billion).
NanJing Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
NanJing Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.62 Billion to $968.69 Million (-3.38% CAGR).
NanJing Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NanJing Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
NanJing Pharmaceutical Co Ltd's market cap is 0.02 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.55x
NanJing Pharmaceutical Co Ltd's market cap is 1.55 times its annual earnings
11.18x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.62 Billion | $24.81 Billion | $156.72 Million | 0.07x | 10.32x |
| 2016 | $1.23 Billion | $26.72 Billion | $180.27 Million | 0.05x | 6.84x |
| 2017 | $970.53 Million | $27.47 Billion | $232.44 Million | 0.04x | 4.18x |
| 2018 | $676.48 Million | $31.30 Billion | $264.29 Million | 0.02x | 2.56x |
| 2019 | $759.70 Million | $37.16 Billion | $346.92 Million | 0.02x | 2.19x |
| 2020 | $739.04 Million | $39.82 Billion | $376.41 Million | 0.02x | 1.96x |
| 2021 | $832.89 Million | $45.12 Billion | $505.18 Million | 0.02x | 1.65x |
| 2022 | $890.87 Million | $50.22 Billion | $595.67 Million | 0.02x | 1.50x |
| 2023 | $863.44 Million | $53.59 Billion | $577.83 Million | 0.02x | 1.49x |
| 2024 | $884.84 Million | $53.70 Billion | $570.63 Million | 0.02x | 1.55x |
Competitor Companies of 600713 by Market Capitalization
Companies near NanJing Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to NanJing Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $830.88 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #17 globally with a market cap of $572.79 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #28 globally with a market cap of $387.90 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $295.24 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $830.88 Billion | $930.35 |
| #17 | Johnson & Johnson | NYSE:JNJ | $572.79 Billion | $238.11 |
| #28 | AbbVie Inc | NYSE:ABBV | $387.90 Billion | $219.76 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $295.24 Billion | $191.29 |
NanJing Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, NanJing Pharmaceutical Co Ltd's market cap moved from $1.62 Billion to $ 968.69 Million, with a yearly change of -3.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥968.69 Million | -0.55% |
| 2025 | CN¥974.04 Million | +10.08% |
| 2024 | CN¥884.84 Million | +2.48% |
| 2023 | CN¥863.44 Million | -3.08% |
| 2022 | CN¥890.87 Million | +6.96% |
| 2021 | CN¥832.89 Million | +12.70% |
| 2020 | CN¥739.04 Million | -2.72% |
| 2019 | CN¥759.70 Million | +12.30% |
| 2018 | CN¥676.48 Million | -30.30% |
| 2017 | CN¥970.53 Million | -21.24% |
| 2016 | CN¥1.23 Billion | -23.83% |
| 2015 | CN¥1.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NanJing Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $968.69 Million USD |
| MoneyControl | $968.69 Million USD |
| MarketWatch | $968.69 Million USD |
| marketcap.company | $968.69 Million USD |
| Reuters | $968.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.